Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Young women in sub-Saharan Africa bear a disproportionate burden of HIV infection compared to men but have limited options to reduce their HIV risk. Microbicides could fill an important HIV prevention gap for sexually active women who are unable to successfully negotiate mutual monogamy or condom use. Purpose: This paper describes the baseline sample characteristics in the CAPRISA 004 trial which assessed the safety and effectiveness of the vaginal microbicide, 1% tenofovir gel for HIV prevention in South Africa. Methods: This analysis assessed the baseline demographic, clinical and sexual behavior data of women screened and enrolled into the trial. The characteristics were summarized using descriptive summary measures; expressed as means and percent for categorical variables. Results: HIV prevalence at screening was 25.8% [95% Confidence Interval (CI):23.9-27.7). Of the 889 eligibly enrolled women who contributed follow-up data, rural participants recruited from a family planning (FP) clinic were younger, more likely to be living apart from their regular partner, reported lower coital frequency, had lower condom use (p < 0.001). In contrast, urban participants recruited from a sexually transmitted disease (STD) clinic reported higher numbers of lifetime sexual partners, new partners in the last 30 days and receiving money in exchange for sex (p < 0.001). Conclusion: The populations selected provide suitable diverse target groups for HIV prevention intervention studies. Trial registration: ClinicalTrials.gov: http://www.clinicaltrials.gov/ct2/show/NCT00441298
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science · doi:10.1126/science.1193748 · Cited by 2,435 · cited 4×
“a Parts of the data reported in Table 2 have previously been reported [22]1 observation missing c 4 observations missing d 5 observations missing - Missing values were excluded from percentage calculation $ Genital symptoms of vaginal burning, pruritis, pain after sex, intermenstrual bleeding or burning and frequency…”
BackgroundMethodInfluentialSelf-citationPettifor, A. E., Rees, H. V., Kleinschmidt, I., Steffenson, A. E., MacPhail, C., Hlongwa-Madikizela, L., Vermaak, K., & Padian, N. S. (2005) · AIDS · doi:10.1097/01.aids.0000183129.16830.06 · Cited by 645 · cited 1×
“The majority of HIV infected women live in Sub-Saharan Africa and young women in this region have a 3-6 fold higher burden of HIV infection compared to men [1,3,4].”
BackgroundSkoler-Karpoff, S., Ramjee, G., Ahmed, K., Altini, L., Plagianos, M. G., Friedland, B., Govender, S., De Kock, A., Cassim, N., Palanee, T., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61842-5 · Cited by 502 · cited 1×
“Topical microbicides offer an option for these women to reduce their HIV risk and to date several classes of products have undergone advanced clinical testing [15-20].”
BackgroundHIV/AIDS in Women: An Expanding Epidemic
Quinn, T. C., & Overbaugh, J. (2005) · Science · doi:10.1126/science.1112489 · Cited by 417 · cited 1×
“South Africa has the highest burden of prevalent and incident HIV infections, with the province of KwaZuluNatal at the epicenter of the pandemic [5-10].”
BackgroundSAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria.
Feldblum, P. J., Adeiga, A., Bakare, R., Wevill, S., Lendvay, A., Obadaki, F., Olayemi, M. O., Wang, L., Nanda, K., & Rountree, W. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001474 · Cited by 280 · cited 1×
“Topical microbicides offer an option for these women to reduce their HIV risk and to date several classes of products have undergone advanced clinical testing [15-20].”
Background
Cited by
Sivro, A., Schuetz, A., Sheward, D., Joag, V., Yegorov, S., Liebenberg, L. J., Yende-Zuma, N., Stalker, A., Mwatelah, R. S., Selhorst, P., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam6354 · Cited by 94
Self-citationTenofovir gel for the prevention of herpes simplex virus Type 2 infection.
Abdool Karim, S. S., Abdool Karim, Q., Kharsany, A. B. M., Baxter, C., Grobler, A. C., Werner, L., Kashuba, A., Mansoor, L. E., Samsunder, N., Mindel, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410649 · Cited by 92
Self-citationPillay, D., & Wassenaar, D. R. (2018) · South African Journal of Psychology · doi:10.1177/0081246317708094 · Cited by 6
Metadata
- Authors
- Karim, Q. A., Kharsany, A. B., Frohlich, J. A., Baxter, C., Yende, N., Mansoor, L. E., Mlisana, K. P., Maarschalk, S., Arulappan, N., Grobler, A., Sibeko, S., Omar, Z., Gengiah, T. N., Mlotshwa, M., Samsunder, N., & Abdool Karim, S. S.
- Venue
- Trials
- Published
- 2011-03-07
- Volume
- 12
- Issue
- 1
- Pages
- 67-67
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2114527378
- Cited by
- 37
- References
- 5
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. https://app.cochat.ai/papers/10.1186/1745-6215-12-67
- The paper
- Karim, Q. A., Kharsany, A. B., Frohlich, J. A., Baxter, C., Yende, N., Mansoor, L. E., Mlisana, K. P., Maarschalk, S., Arulappan, N., Grobler, A., Sibeko, S., Omar, Z., Gengiah, T. N., Mlotshwa, M., Samsunder, N., & Abdool Karim, S. S. (2011). Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials. https://doi.org/10.1186/1745-6215-12-67
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.